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A series of new coumarin-derived carboxylate ligands and their silver(I) complexes have been synthesized, characterized and screened
for their in vitro antibacterial activity against a range of Gram-positive and Gram-negative bacteria as well as for their antifungal activity
against a clinical isolate of Candida albicans. The ligands were synthesised by either acid or base hydrolysis of their corresponding esters,
which in turn were synthesised via the Knoevenegal reaction. The reaction of silver(I) nitrate with the coumarin carboxylate ligands in
either aqueous or aqueous/ethanol solutions allowed the isolation of a series of novel Ag(I) carboxylate complexes. Whilst none of the
ligands showed any antimicrobial activity, a number of the Ag(I) complexes exhibited potent activity. In particular, Ag(I) complexes of
hydroxy-substituted coumarin carboxylates demonstrated potent activity against the clinically important methicillin-resistant Staphylo-
coccus aureus (MRSA) bacterium (MIC80 = 0.63 lM).
 2006 Elsevier B.V. All rights reserved.
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Coumarin (2H-1-benzopyran-2-one), a naturally occur-
ring plant constituent, has been used in the treatment of
cancer [1] and oedemas [2], and many of its derivatives have
also shown biological activity. Biological effects observed
include antibacterial [3], anti-thrombotic and vasodilatory
[4], anti-mutagenic [5] and anti-tumourigenic [6–9] effects
as well as acting as lipoxygenase and cyclooxygenase inhib-
itors [10,11]. A number of recent studies have highlighted
the antimicrobial activity of naturally derived and synthetic
coumarins [12–14]. Lately, a number of metal complexes of
coumarins have been synthesised and their biological activ-
ity determined. Kostova et al. have shown the cytotoxic0020-1693/$ - see front matter  2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.ica.2006.04.006
* Corresponding author. Tel.: +353 1 4042889; fax: +353 1 4042700.
E-mail address: bernie.creaven@it-tallaght.ie (B.S. Creaven).potential of coumarins complexed with cerium, lanthanum,
zirconium and neodymium [15–19]. We have previously
been concerned with two main areas of coumarin chemis-
try, namely the chemotherapeutic [20–26] and antimicro-
bial [27] activity of functionalised coumarins. In the latter
work a series of copper(II) and silver(I) complexes of
hydroxynitrocoumarins were prepared and their antimicro-
bial activity assessed against a series of Gram-positive and
Gram-negative bacterial strains and also against a clinical
isolate of C. albicans. While none of the coumarin-based
ligands or the simple copper(II) perchlorate salt showed
any significant antimicrobial activity, AgNO3 and its cou-
marin complexes effectively inhibited the growth of the
clinically important methicillin-resistant Staphylococcus
aureus (MRSA) bacterium. These complexes also demon-
strated good activity, comparable to that of the commercial
fungicides clortrimazole and ketoconazole, against the fun-
gal pathogen C. albicans. Both of these human pathogenic
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ment of resistance to current drug therapies. A recent study
showed that ca. 44% of S. aureus bacteremia isolates in
Britain and in the Republic of Ireland were resistant to
methicillin [28]. Also of concern is the growth in the popu-
lation of immunosuppressed individuals and the increase in
the numbers and types of fungal infections noted in these
patients. Candidemia is a serious complication in patients
undergoing treatment for cancer [29,30].
It is well known that silver ions and silver-based com-
pounds are highly toxic to microorganisms [31,32] showing
strong biocidal effects. Therefore as an advancement of our
previous studies, we have now prepared a series of Ag(I)
complexes of coumarin-3-carboxylic acid (2-oxo-2H-benzo
pyran-3-carboxylic acid) and investigated their antimicro-
bial activity. Carboxylate ligands are known to form a
range of complexes with Ag(I) and some of these have pro-
ven anti-Candida activity [33].
2. Experimental
2.1. General methods
Chemicals and solvents were purchased from Sigma-
Aldrich Co. (Dorset, UK) and used without further purifi-
cation. Infrared spectra of solids (in a KBr matrix) were
recorded in the region 4000–400 cm1 on a Nicolet Impact
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Scheme 1. General reaction scheme for the synthesis oing points were recorded on a Stuart Scientific SMP-1
apparatus (up to 300 C). A JEOL JNM-LA300 FT-
NMR spectrometer was used to record 1H NMR spectra
(5 to 15 ppm from TMS) and 13C NMR spectra (33
to 233 ppm from TMS) as solutions in d6-DMSO. Micro-
analytical data were provided by the Microanalytical Lab-
oratory, National University of Ireland, Dublin, Belfield,
Dublin 4.
2.2. Syntheses of ligands
2.2.1. Synthesis of ethyl 6-hydroxycoumarin-3-carboxylate
[6-OHCcaEt] (1) and the substituted esters (2–13) given in
Scheme 1
2,5-Dihydroxybenzaldehyde (0.50 g, 3.6 mmol) and
diethyl malonate (0.64 g, 0.70 ml, 4.0 mmol, 10 mol%
excess) were heated with stirring in ethanol (95%, 20 ml)
until dissolution occurred. Addition of piperidine (0.4 ml,
0.34 g, 4.0 mmol) to the solution resulted in a colour
change from green to brown. The solution was refluxed
for 6 h and on cooling a green crystalline solid formed.
Crystals of ethyl 6-hydroxycoumarin-3-carboxylate (1)
were isolated by filtration and washed with cold ethanol
(0 C). The solid was recrystallised from ethanol, filtered
and washed with cold ethanol again. The crystals were
dried in a vacuum oven at 50 C for 2 days. The ester deriv-
atives (2–13) shown in Scheme 1, which were the precursors
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17   R1= R2 = H, R3 = OEt
18 R1= Cl, R2 = R3 = H
19   R1= Br, R2 = R3 = H
20 R1= R3 = Br, R2 = H
21   R1= NO2, R2 = R3 = H
22   R1= R3 = H, R2 = OMe
23 R1= R3 = I, R2 = H
24   R1= NO2, R2 = H, R3 = OMe
25   R1= R3 = Cl, R2 = H
26   R1= R3 = t-Bu, R2 = H,
f coumarin-based esters (1–13) and acids (14–26).
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prepare 1 and using the appropriate substituted aldehyde.
All compounds were isolated as solids and the purity of
each precursor was confirmed by 1H and 13C NMR spec-
troscopy, IR spectroscopy, m.p. and TLC analysis (given
as supplementary data in Tables S1–S3).
2.2.2. Synthesis of 6-hydroxycoumarin-3-carboxylic acid [6-
OHCcaH] (14), 7-hydroxycoumarin-3-carboxylic acid [7-
OHCcaH] (15) and 8-hydroxycoumarin-3-carboxylic acid
[8-OHCcaH] (16)
A solution of ethyl 6-hydroxycoumarin-3-carboxylate
(1) (2.50 g, 10.7 mmol) in water (50 ml) containing concen-
trated hydrochloric acid (37%, 5 ml) was refluxed for 6 h
leaving a green/yellow solution. Upon cooling, a green pre-
cipitate formed. The solid was isolated by filtration and
washed with water and ethanol and then placed in a vac-
uum oven at 50 C for three days. The analytical data for
this compound, 6-hydroxycoumarin-3-carboxylic acidTable 1
Physical, spectral and analytical data for the ligands (14–26)
Ligand/molecular formula Colour Yield (%) Rf
a MP (
6-OHCcaH (14)/C10H6O5 green 88 0.13 >300
7-OHCcaH (15)/C10H6O5 orange 58 0.11 262–2
8-OHCcaH (16)/C10H6O5 yellow 94 0.14 >300
8-EtOCcaH (17)/C12H10O5 white 90 0.17 192–1
6-ClCcaH (18)/C10H5ClO4 white 95 0.13 186–1
6-BrCcaH (19)/C10H5BrO4 white 87 0.10 213–2
6,8-diBrCcaH (20)/C10H4Br2O4 white 92 0.13 233–2
6-NO2CcaH (21)/C10H5NO6 brown 85 0.11 244–2
7-MeOCcaH (22)/C11H8O5 off-white 90 0.20 208–2
6,8-diICcaH (23)/C10H4I2O4 yellow 92 0.14 240–2
8-MeO-6-NO2CcaH (24)/C11H7NO7 brown 87 0.17 224–2
8-MeO-6-NO2CcaH (25)/C10H4Cl2O4 white 96 0.12 220–2
6,8-di-t-butylCcaH (26)/C18H22O4 white 58 0.71 106–1
a Mobile phase 70:30, ethyl acetate:hexane.
b MP’s are uncorrected.
c All IR spectra were run as KBr disc.
Table 2
1H NMR data for substituted coumarin-3-carboxylic acids 14–26 recorded in
Coumarin acid 1H NMR signal: d, multiplicity, J value (Hz)
H4 H5 H6
6-OHCcaH (14) 8.66, s 7.21, d, J = 8.8 (9.9)
7-OHCcaH (15) 8.69, s 7.76, d, J = 8.6 6.83, dd, J
8-OHCcaH (16) 8.69, s 7.21, pt, J = 8.2 7.32, q, J =
8-EtOCcaH (17) 8.72, s 7.43, dd, J = 1.5, 7.5 7.31, pt, J=
6-ClCcaH (18) 8.70, s 8.04, d, J = 2.6 Cl
6-BrCcaH (19) 8.69, s 8.16, pt, J = 2.0 Br
6,8-diBrCcaH (20) 8.68, s 8.18, d, J = 2.4 Br
6-NO2CcaH (21) 8.89, s 8.90, d, J = 2.7 NO2
7-MeOCcaH (22) 8.72, s 7.83, d, J = 8.4 7.00, dd, J
6,8-diICcaH (23) 8.60, s 8.28, d, J= 2.0 I
8-MeO-6-NO2CcaH (24) 8.83, s 8.47, pt, J = 2.4, 1.6 NO2
8-MeO-6-NO2CcaH (25) 8.71, s 8.04, d, J = 2.6 Cl
6,8-di-t-butylCcaH (26) 8.22, s 7.13, d, J = 2.2 t-butyl
Atom numbering for assignment of NMR signals is given in Fig. 1.
Values given in brackets are OH signals, s, singlet; d, doublet; t, triplet; q, qu[6-OHCcaH] (14), and all the remaining coumarin carbox-
ylate derivatives synthesised are given in Table 1. The 1H
and 13C NMR spectral data for this compound and all of
the following carboxylic acid derivatives of coumarin are
given in Tables 2 and 3. The atom numbering system used
for the assignment of the 1H and 13C NMR spectra of the
coumarin-based carboxylic acids (14–26) is shown in Fig. 1.
The carboxylate derivatives 7-hydroxycoumarin-3-car-
boxylic acid [7-OHCcaH] (15) and 8-hydroxycoumarin-3-
carboxylic acid [8-OHCcaH] (16) were synthesised by the
same method as that employed to prepare (14) except com-
pounds (2) and (3), respectively, were used as the precursor
ester.
2.2.3. Synthesis of 8-ethoxycoumarin-3-carboxylic acid
[8-EtOCcaH] (17) and the substituted carboxylic acids
(18–26)
A solution comprising sodium hydroxide (2 M, 30 ml),
ethanol (95%, 10 ml) and ethyl 8-ethoxycoumarin-3-carbox-C)b Calc. (found) IR (cm1)c
%C %H %N mO–H mC@O (lactone)
58.26 (58.22) 2.93 (2.88) 3163 1739
66 58.26 (58.20) 2.93 (2.88) 3122 1710
58.26 (58.18) 2.93 (2.85) 3112 1735
95 61.54 (61.29) 4.30 (4.04) 3426 1747
88 53.47 (53.36) 2.24 (2.32) 3442 1752
16 44.64 (44.50) 1.87 (1.59) 3434 1764
36 34.52 (34.38) 1.16 (1.02) 3443 1771
46 51.08 (51.06) 2.14 (2.14) 5.96 (5.72) 3429 1720
10 60.00 (59.69) 3.66 (3.34) 3434 1732
42 27.18 (27.16) 0.91 (0.77) 3436 1742
27 49.82 (49.76) 2.66 (2.53) 5.28 (5.08) 3437 1746
24 46.37 (46.28) 1.56 (1.58) 3470 1778
08 71.50 (71.43) 7.33 (7.45) 3417 1745
d6 DMSO
H7 H8 COOH
7.16, dd, J = 2.9, 8.8 7.30, d, J = 2.7 (13.2)
= 2.2, 8.8 (11.07) 6.74, d, J = 2.2 (11.1)
8.6, 9.3 7.20, t, J = 8.2 (10.4) (13.2)
7.7, 8.1 7.39, dd, J = 1.3, 8.1 OEt (13.3)
7.75, dd, J = 2.6, 9.0 7.47, d, J = 9.0 (13.4)
7.86, dd, J = 2.0, 8.8 7.41, dd, J=1.5, 8.8 (13.4)
8.24, d, J = 2.4 Br (13.5)
8.49, dd, J = 2.7, 9.2 7.64, d, J = 9.0 (13.5)
= 2.4, 8.2 OMe 7.03, d, J = 2.4 (13.0)
8.42, d, J = 2.0 I (13.5)
8.03, pt, J = 2.4, 1.5 OMe (13.5)
8.02, d, J = 2.6 Cl (13.5)
7.28, d, J = 2.2 t-butyl
artet; dd, double–doublet; pt, pseudo-triplet.
Table 3
13C NMR data for substituted coumarin-3-carboxylic acids recorded in d6-DMSO
Coumarin acid 13C NMR signal in ppm
Carbon no.
2 3 4 5 6 7 8 9 10 COOH
6-OHCcaH (14) 157 118 148 113 153 117 118 147 122 164
7-OHCcaH (15) 164 114 149 132 110 157 101 157 112 164
8-OHCcaH (16) 156 118 144 120 124 120 148 143 118 164
8-EtOCcaH (17) 156 117 148 121 124 118 145 143 118 164
6-ClCcaH (18) 156 119 147 128 128 133 118 153 119 163
6-BrCcaH (19) 156 119 146 131 116 136 118 153 119 163
6,8-DiBrCcaH (20) 155 120 146 131 116 138 110 150 120 163
6-NO2CcaH (21) 158 120 147 126 143 128 117 155 118 163
7-MeOCcaH (22) 164 111 149 131 113 156 100 157 113 164
6,8-DiICcaH (23) 155 119 146 138 89 149 86 153 120 163
8-MeO-6-NO2CcaH (24) 155 120 147 109 146 116 143 148 118 163
6,8-DiClCcaH (25) 155 120 146 128 128 132 120 148 120 163
6,8-Di-t-ButylCcaH (26) 156 117 151 124 135 128 146 149 118 163
Atom numbering for assignment of NMR signals is given in Fig. 1.





















Fig. 1. 1H and 13C NMR atom labels for the analysis of the coumarin-3-
carboxylic acids and their Ag(I) complexes.
B.S. Creaven et al. / Inorganica Chimica Acta 359 (2006) 3976–3984 3979ylate (4) (0.75 g, 3.0 mmol) was refluxed for 2 h. On cooling,
hydrochloric acid was added to the yellow solution until a
white precipitate formed which was isolated by filtration,
washed with water and cold ethanol and then placed in an
oven at 50 C for 3 days. Ligands 18–26 were all prepared
by this method using compounds 5–13, respectively, as the
precursor esters. Analytical data for all of the ligands are
given in Tables 1–3.
2.3. Syntheses of substituted coumarin-3-
carboxylatosilver(I) complexes
Syntheses of the Ag(I) complexes were conducted in the
absence of light and all complexes were stored in the dark.
Microanalytical, 1H and 13C NMR spectral data for the
following Ag(I) complexes (27–40) are given in Tables 4–
6. The atom numbering system used for the assignment
of 1H and 13C NMR spectra of the complexes are shown
in Fig. 1. The main IR spectral bands for the complexes
are given in Table 7.
2.3.1. Synthesis of coumarin-3-carboxylatosilver(I) (27)
[Ag(Cca)]
A solution of silver(I) nitrate (0.170 g, 1.00 mmol) in
water (10 ml) was added to a heated solution of couma-rin-3-carboxylic acid (0.191 g, 1.00 mmol) in hot methanol
(10 ml) over a period of 10 min resulting in the formation
of a white precipitate. The suspension was left to stir for
1 h and the solid product isolated by filtration, washed with
hot methanol and then with cold water and then dried in
the dark in a vacuum oven at 50 C for 7 days.
2.3.2. Synthesis of 6-hydroxycoumarin-3-




A solution of 6-hydroxycoumarin-3-carboxylic acid (14)
(0.150 g, 1.00 mmol) and sodium hydroxide (0.030 g,
1.00 mmol) in water (10 ml) was added to a solution of sil-
ver(I) nitrate (0.124 g, 1.00 mmol) in water (10 ml) over a
period of 10 min at room temperature, resulting in the for-
mation of a yellow precipitate. The suspension was left to
stir for 1 h and was the resulting precipitate isolated by fil-
tration. The resulting solid, 6-hydroxycoumarin-3-carboxy-
latosilver(I) [Ag(6-OHCca)] (28), was washed with hot
methanol and then with cold water. The solid was then
dried in the dark in a vacuum oven at 50 C for 7 days.
7-Hydroxy-coumarin-3-carboxylatosilver(I) [Ag(7-OHC-
ca)] (29) and 8-hydroxy-coumarin-3-carboxylatosilver(I)
[Ag(8-OHCca)] (30) were synthesised by the same method
except that acids 15 and 16, respectively, were used as
ligands.
2.3.3. Synthesis of 8-ethoxy-coumarin-3-
carboxylatosilver(I) [Ag(8-EtOCca)] (31) and the
silver(I) complexes (32–40)
A solution of silver(I) nitrate (0.758 g, 4.46 mmol) in
water (20 ml) was added over a period of 10 min at room
temperature to a heated solution of 8-ethoxycoumarin-3-
carboxylic acid (17) (1.00 g, 4.46 mmol) and sodium
hydroxide (0.196 g, 4.91 mmol) in methanol/water (1:1,
Table 4
Physical, spectral and analytical data for the Ag(I) complexes (14–26)
Complex/molecular formula Colour Yield (%) MP (C)a Calc. (found)
%C %H %N
[Ag(Cca)] (27)/C10H5AgO4 white 76 294–296 40.44 (39.88) 1.70 (1.56)
[Ag(6-OHCca)] (28)/C10H5AgO5 yellow 65 270–272 38.37 (37.16) 1.61 (2.08)
[Ag(7-OHCca)] (29)/C10H5AgO5 red/black 83 248–252 38.37 (38.98) 1.61 (1.65)
[Ag(8-OHCca)] (30)/C10H5AgO5 red/black 74 274–276 38.37 (37.86) 1.61 (1.30)
[Ag(8-EtOCca)] (31)/C12H9AgO5 yellow/orange 28 246–248 42.26 (42.61) 2.66 (2.22)
[Ag(6-ClCca)] (32)/C10H4AgClO4 yellow 82 >300 36.24 (36.75) 1.22 (1.09)
[Ag(6-BrCca)] (33)/C10H4AgBrO4 yellow/brown 79 >300 31.95 (32.28) 1.07 (1.02)
[Ag(6,8-diBrCca)] (34)/C10H3AgBr2O4 yellow 62 268–270 26.41 (26.26) 0.66 (0.38)
[Ag(6-NO2Cca)] (35)/C10H4AgNO6 yellow 63 293–296 35.12 (35.02) 1.18 (0.91) 4.10 (3.39)
[Ag(7-MeOCca)] (36)/C11H7AgO5 yellow/orange 77 272–274 40.40 (39.82) 2.16 (1.55)
[Ag(6,8-diICca)] (37)/C10H3AgI2O4 yellow 89 277–280 21.89 (21.59) 0.55 (0.29)
[Ag(8-MeO-6-NO2Cca)] (38)/C11H6AgNO7 yellow/orange 75 275–278 35.51 (35.42) 1.63 (1.38) 3.76 (3.52)
[Ag(6,8-diClCca)] (39)/C10H3AgCl2O4 yellow/orange 89 277–280 32.82 (32.87) 0.83 (0.57)
[Ag(6,8-di-t-butylCca)] (40)/C18H21AgO4 white 70 233–236 52.83 (52.16) 5.17 (4.92)
a MP’s are uncorrected.
Table 5
1H NMR data for substituted coumarin-3-carboxylatosilver(I) complexes (27–40) recorded in d6-DMSO
Complex 1H NMR signals: d, multiplicity, J value in Hz,
H4 H5 H6 H7 H8
[Ag(Cca)] (27) 8.21, s 7.77, dd, J = 1.4, 7.7 7.60, dd, J = 1.6, 7.4 7.30, td, J = 7.3, 7.8 7.35, dd, J = 1.1, 7.7
[Ag(6-OHCca)] (28) 8.14, s 7.08, d, J = 2.9 (9.81) 7.03, dd, J = 3.0, 8.8 7.21, d, J = 8.8
[Ag(7-OHCca)] (29) 8.35, s 7.62, d, J = 8.6 6.78, dd, J = 2.2, 8.4 not observed 6.69, d, J = 2.2
[Ag(8-OHCca)] (30) 8.24, s 7.20, dd, J = 2.6, 8.8 7.13, dd, J = 6.8, 7.9 7.12, pt, J = 8.1 (10.29)
[Ag(8-EtOCca)] (31) 8.14, s 7.31, dd, J = 2.4, 6.8 7.24, pt, J = 6.6, 8.0 7.26, dd, J = 7.7 OEt
[Ag(6-ClCca)] (32) 7.96, s 7.86, d, J = 2.6 Cl 7.56, dd, J = 2.6, 8.8 7.37, d, J = 8.8
[Ag(6-BrCca)] (33) 8.01, s 8.00, d, J = 2.4 Br 7.69, dd, J = 2.4, 8.8 7.31, d, J = 8.8
[Ag(6,8-diBrCca)] (34) 8.13, s 8.06, d, J = 2.2 Br 8.09, d, J = 2.2 Br
[Ag(6-NO2Cca)] (35) 8.31, s 8.78, d, J = 2.8 NO2 8.37, dd, J = 2.8, 9.2 7.58, d, J = 9.0
[Ag(7-MeOCca)] (36) 8.23, s 7.68, d, J = 8.6 6.92, dd, J = 2.4, 8.4 OMe 6.97, d, J = 2.4
[Ag(6,8-diICca)] (37) 8.04, s 8.16, d, J = 1.6 I 8.29, d, J = 1.6 I
[Ag(8-MeO-6-NO2Cca)] (38) 8.27, s 7.95, d, J = 2.4 NO2 8.38, d, J = 2.6 OMe
[Ag(6,8-diClCca)] (39) 8.11, s 7.90, d, J = 2.4 Cl 7.90, d, J = 2.8 Cl
[Ag(6,8-di-t-butylCca)] (40) 8.18, s 7.63, d, J = 2.2 t-butyl 7.57, d, J = 2.4 t-butyl
Atom numbering for assignment of NMR signals is given in Fig. 1.
Values shown in brackets are OH signals, s, singlet; d, doublet; t, triplet; q, quartet; dd, double–doublet; pt, pseudo-triplet; td, triple doublet.
3980 B.S. Creaven et al. / Inorganica Chimica Acta 359 (2006) 3976–398420 ml) resulting in the formation of a yellow/orange precip-
itate. The suspension was stirred for 1 h, filtered, and the
solid washed with hot methanol followed by cold water.
The yellow solid was then dried in the dark in a vacuum
oven 50 C for 7 days. The silver(I) complexes 32–40 of
ligands 18–26 were synthesised on a similar scale by the
method used to prepare 31.
2.4. Antimicrobial studies
Bacterial and fungal isolates: All bacterial isolates were
obtained clinically: S. aureus (urinary track infection),
methicillin resistant S. aureus (MRSA) (wound infection),
S. simulans (facial skin), Micrococcus luteus (facial skin),
Escherichia coli (gastro-intestinal tract), Bacillus oleronius
(facial skin), Pantonea agglumerans (facial skin).
The fungal isolate C. albicans ATCC 10231 was
obtained from the American Type Culture Collection
(MD, USA).2.4.1. Assessment of antibacterial activity
Ligands 14–26, the commercially available ligand cou-
marin-3-carboxylic acid(coumarin-3-carboxylic acid,
CcaH) and the Ag(I) complexes 27–40, were tested against
four Gram-positive and three Gram-negative strains to
determine their antibacterial activity. Bacterial strains were
grown overnight in nutrient broth medium at 30 C and
200 rpm in an orbital incubator. The absorbance of these
cultures was measured at 660 nm and cultures were diluted
to an optical density of 0.1. The cell suspension (100 ll)
was added to the wells of a 96 well plate containing test
compound dissolved in nutrient broth medium in serial
dilutions from 100–0.25 lg/cm3. Plates were incubated
at 30 C for 24 h and the optical density was measured
spectrophotometrically (Dynex Technology) at 450 nm.
2.4.2. Antifungal susceptibility testing
Antifungal susceptibility testing was performed using
broth microdilution assays according to the National
Table 7










[Ag(Cca)] (27) 1733 1596 1384 212
[Ag(6-OHCca)] (28) 1707 1586 1385 201
[Ag(7-OHCca)] (29) 1708 1577 1376 201
[Ag(8-OHCca)] (30) 1718 1592 1382 210
[Ag(6-ClCca)] (31) 1711 1590 1378 212
[Ag(8-EtOCca)] (32) 1742 1575 1375 200
[Ag(6-BrCca)] (33) 1741 1589 1376 223
[Ag(6,8-diBrCca)] (34) 1738 1604 1371 234
[Ag(6-NO2Cca)](35) 1739 1599 1377 222
[Ag(7-MeOCca)] (36) 1718 1597 1378 219
[Ag(6,8-diICca)] (37) 1729 1589 1374 222
[Ag(8-MeO-6-NO2Cca)] (38) 1762 1604 1370 234
[Ag(6,8-diClCca)] (39) 1730 1595 1369 226
[Ag(6,8-di-t-butylCca)] (40) 1709 1583 1394 199
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M27-A2) protocol with slight modifications. M27-A2
method was altered by substituting antibiotic medium 3
for RPMI 1640 medium. Using this method MIC80’s were
determined spectrophotometrically at 405 nm by compar-
ing the turbidity of growth in each well. MIC80 is defined
as the lowest concentration of drug that inhibits fungal
growth by 80%.
3. Results and discussion
3.1. Synthesis and characterisation of the complexes
The coumarin carboxylate ligands 14–26 were isolated
by first preparing their corresponding esters 1–13 using
the Knoevenagal reaction (Scheme 1). This reaction, which
involved refluxing the appropriate substituted salicylalde-
hyde with diethyl malonate in ethanol in the presence of
a catalytic base piperidine, allowed the isolation of the ser-
ies of esters in high yields. In general, the solutions were
refluxed for ca. 2 days and the precipitated products were
subsequently recrystallised from ethanol and characterized
by standard techniques. Isolation of the acid derivatives
14–16 was then achieved by refluxing the corresponding
esters 1–3 for 6 h in distilled water with a catalytic amount
of hydrochloric acid. Upon cooling, the products precipi-
tated and were recrystallised from ethanol. The acid deriv-
atives 17–26 could be synthesized in the same manner but
gave higher yields when made by base hydrolysis. In all
cases, the acids were recrystallised from ethanol. All of
the carboxylate ligands 14–26 were fully characterised by
elemental analysis, m.p., TLC and by IR, 1H and 13C
NMR spectroscopy (Tables 1–3).
The silver(I) complex of commercially available couma-
rin-3-carboxylic acid (CcaH), [CcaAg] (27), was synthes-
ised by a metathesis reaction with silver nitrate in a 1:1
ratio. Isolation of the silver(I) complexes of 6-, 7- and 8-Table 6
13C NMR data for substituted coumarin-3-carboxylatosilver(I) complexes (27
Complex 13C NMR signal in ppm
Carbon no.
2 3 4 5
[Ag(Cca)] (27) 157 125 142 128
[Ag(6-OHCca)] (28) 158 126 141 112
[Ag(7-OHCca)] (29) 162 119 144 130
[Ag(8-OHCca)] (30) 157 126 142 118
[Ag(8-EtOCca)] (31) 157 126 142 119
[Ag(6-ClCca)] (32) 157 128 138 127
[Ag(6-BrCca)] (33) 157 128 139 130
[Ag(6,8-diBrCca)] (34) 156 129 139 130
[Ag(6-NO2Cca)] (35) 157 124 143 126
[Ag(7-MeOCca)] (36) 162 118 142 129
[Ag(6,8-diICca)] (37) 157 128 139 130
[Ag(8-MeO-6-NO2Cca)] (38) 156 129 143 107
[Ag(6,8-diClCca)] (39) 157 128 139 127
[Ag(6,8-di-t-butylCca)] (40) 157 123 145 125
Atom numbering for assignment of NMR signals is given in Fig. 1.hydroxy-coumarin-3-carboxylic acids (28–30) by this
method proved problematic. These silver(I) complexes
were ultimately synthesised in aqueous solution by depro-
tonation of the acid using NaOH, followed by the addition
of silver nitrate. The remaining silver(I) complexes were
isolated in a similar fashion, except that ethanol:water
was used as the reaction solvent. In all cases the products
precipitated out of solution, and when dried and stored
in the dark they appeared to be air and moisture stable.
The complexes were insoluble in water and common
organic solvents with the exception of DMSO. Elemental
analyses were in agreement with the proposed 1:1
ligand:silver formulation for all complexes.
3.1.1. IR spectra
The masym (OCO) and msym (OCO) vibrational frequen-
cies, together with the Dm(OCO) values for the carboxylate
group of the silver(I) complexes (27–40), are listed in Table
7. All of the complexes produced a Dm(OCO) value of–40) recorded in d6-DMSO
6 7 8 9 10 COOH
115 132 124 153 118 166
153 119 118 146 120 167
113 157 101 155 110 166
124 118 144 142 119 167
124 119 145 142 115 166
127 131 117 151 120 166
115 133 118 152 120 166
115 135 109 149 121 165
139 129 117 156 119 166
114 155 100 157 112 165
118 133 115 152 120 166
146 115 139 146 119 165
120 130 120 142 121 166
135 126 142 150 118 166
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tion to the silver(I) centre [34]. A similar monodentate car-
boxylate coordination mode has been reported for the
structurally characterised Ag(I) salicylate complexes [Ag-
(l3-hexamethylenetetramine)(salH)2] [35] and [Ag2(NH3)2-
(salH)2] [33]. The band located at between 1770 and
1710 cm1 in all of the carboxylate ligands, which is attrib-
uted to mC@O of the lactone ring, is shifted in all of the com-
plexes by between 10 and 40 cm1 upon formation of the
silver(I) complex except for complexes 35 and 38 whose
coumarin ligand contain nitro groups on the aromatic.
For [Ag(6-NO2Cca)] (35) and [Ag(8-MeO-6-NO2Cca)]
(38), the frequency of the mC@O group of the lactone ring
increased by about 20 cm1 upon complex formation. We
have previously isolated a number of nitrated coumarin
Ag(I) complexes where binding of the coumarin ligand to
the metal centre via the oxygen atoms of the nitro group
was confirmed by both NMR spectroscopy and X-ray crys-
tallography [27]. In these complexes, masym (NO2) was
shifted to lower frequency upon formation of a Ag(I) com-
plex. The masym (NO2) band of the free 6-NO2CcaH ligand
at 1535 cm1 increase in frequency by about 20 cm1 upon
formation of the Ag(I) complex 35 whilst masym (NO2) at
1534 cm1 in the free ligand 8-MeO-6-NO2-CcaH is virtu-
ally unchanged upon formation of its silver complex (38).
Thus the masym (NO2) band shifts observed are likely due
to an inductive effect within the coumarin nucleus. It
should be noted that the msym (NO2) is more difficult to
assign unambiguously as there are many overlapping bands
in this spectral region. Repeated attempts to recrystallise
the present Ag(I) complexes were unsuccessful due largely
to their lack of solubility in common solvents.
The IR data, taken together with the insolubility of the
complexes, suggests that they exist in the solid state as
polymeric structures with bonding of Ag(I) likely to both
the deprotonated carboxylate oxygen and lactone carbonyl
oxygen of neighbouring ligands.
3.1.2. NMR spectra
Peak assignments for the 1H and 13C NMR spectra of all
of the Ag(I) complexes (27–40) in DMSO solution are
given in Tables 5 and 6 and were carried out using standard
2D correlation techniques. The signals for the aromatic
hydrogens and carbons of the ligand (H5–H8 and C5–C8,
respectively) showed a distinct downfield shift upon com-
plex formation in both the 1H NMR and 13C NMR spec-
tra. However, the most pronounced shifts (0.5 ppm in
1H NMR and 10 ppm for 13C NMR) were attributed to
the vinyl proton and carbon, respectively (H4, C4) which
are a to the carboxylate group. The 13C NMR signal for
the lactone carbonyl, C2, appears to be largely unaffected
by complex formation. This pattern in chemical shift values
was consistent even amongst complexes having alternative
complexation sites; for example complexes (28–30) which
could form phenoxy type bonds to metal centres [36,37].
The 1H NMR spectra of the present complexes indicated
that the signal assigned to the acid proton (ca. d 13.4ppm), which was present in all of the free ligands, was
absent in all cases while the signal assigned to the hydroxyl
group of complexes (28–30) (d ca. 10–11 ppm) was still
present. It was also noted that while the chemical shift of
C6 in 6-NO2CcaH did move slightly upfield by 4 ppm upon
complex formation, the corresponding signal in the com-
plex formed by 8-MeO-6-NO2CcaH was not affected by
complexation to Ag(I).
It is likely in the solution phase, that binding of the car-
boxylate ligands to the Ag(I) centre is via a unidentate car-
boxylate bond although it is possible that the lactone
carbonyl may also be coordinated to the silver(I) centre
in a chelate fashion. A comparison of the 13C NMR spectra
of the free ligands and their silver(I) complexes (Tables 3
and 6) indicated that the carbons of the carboxylate and
lactone functionalities experience only a slight deshielding
effect upon complex formation. However, in DMSO solu-
tion, the hydroxyl group of the acid of the free ligand is
likely to be H-bonded to the lactone carbonyl oxygen
and causing a deshielding effect on the respective carbonyl
carbon atoms similar to that which would be observed in
the ligand upon formation of a Ag(I) chelate complex.
3.2. Antimicrobial results
The Ag(I) complexes (27–40) and the metal-free ligands
(14–26) were screened for their ability to inhibit the growth
of a number of Gram-positive and Gram-negative bacterial
strains. The Gram-positive strains studied were clinical iso-
lates of S. aureus (SA), methicillin-resistant S. aureus
(MRSA), S. simulans (S. Sim.) and M. luteus (Ml) whilst
the Gram-negative strains were E. coli (E.Coli), B. olenius
(BO) and P. agglumerans (PA). Whilst a number of couma-
rin-based compounds have previously shown good antimi-
crobial activity [12–14] none of the current metal-free
coumarin ligands showed any antibacterial activity over
the test concentration range (data not shown). The growth
inhibition results for the Ag(I) complexes that showed anti-
microbial activity are given in Table 8 as MIC80 values in
lM. The MIC80 value was the minimum concentration
required to inhibit 80% of the growth of the microbe.
The simple silver salt AgNO3 displayed moderate activ-
ity against most of the bacterial strains and good activity
(MIC80 = 16.9 lM) against S. simulans. However, the
Ag(I) complexes of the commercial ligand CcaH (27) and
the hydroxylated derivatives [Ag(6-OHCCa)] (28), [Ag(7-
OHCCa)] (29) and [Ag(8-OHCCa)] (30) all showed good
activity against a broad spectrum of bacterial strains. Of
particular note was the potent activity of [Ag(Cca)] (27)
(MIC80 = 0.63 lM) against the pathogenic MRSA bacte-
rium. This MIC80 value is particularly relevant when com-
pared to the value observed for S. aureus (71.9 lM).
Whilst the hydroxylated derivatives had very good antibac-
terial activity it was surprising that the other Ag(I) com-
plexes were essentially inactive against all of the microbial
species tested. Although the range of functionalities on
the aromatic ring of the coumarin nucleus is considerable
Table 8
Antimicrobial activity, given as the concentration of compound required to inhibit cell growth by 80% [MIC80 (lM)]
Compound MIC80 for test organism (lM)
SA MRSA SSim Ml E.Coli BO PA Can
AgNO3 69.5 123.9 16.9 64.6 69.5 31.4 67.8 66.8
CcaH >2500 >2500 >2500 >2500 >2500 >2500 >2500 331.6
[Ag(Cca)] (27) 71.9 0.63 122.4 100.2 17.5 10.5 55.3 163.4
[Ag(6-OHCca)] (28) 72 76 87.9 66.3 114 94.0 77.6 34.1
[Ag(7-OHCca)] (29) 34.5 35.6 17.3 28.9 36.1 32.1 32.3 69.3
[Ag(8-OHCca)] (30) 140.9 137.6 137.7 114.2 50.0 33.8 38.8 270.0
(SA) Staphylococcus aureus: (MRSA) methicillin-resistant Staphylococcus aureus; (SSim.) Staphylococcus simulans; (Ml) Micrococcus luteus; (E.Coli)
Escherichia coli; (BO) Bacillus olenius; (PA) Pantonea agglumerans; (Can) Candida albicans.
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confers antimicrobial activity on the subsequent Ag(I) com-
plexes. The role of the hydroxyl group in this activity is dif-
ficult to determine but the metal complexes of other
hydroxylated derivatives of coumarin have been previously
shown to have good antimicrobial activity. Examples
include Cu(II) and Ni(II) complexes of 4-hydroxycouma-
rins [36,37]. In a previous study on the antimicrobial activ-
ity of catechols, the position and number of hydroxyl
groups on the aromatic ring were thought to be related to
their relative toxicity towards microorganisms, with evi-
dence that increasing hydroxylation results in an increase
in antimicrobial activity [38]. The mechanism suggested to
be responsible for catechol toxicity to microorganisms
include enzyme inhibition by the oxidized compounds, pos-
sibly through sulphydryl groups or by non-specific interac-
tions with proteins. The results presented here would
indicate that substitution of the hydroxyl groups on the
aromatic ring of the coumarin ligand was also essential
for conferring antimicrobial activity onto the Ag(I)
complexes.
The anti-Candida activity of each of the complexes and
their respective ligands was also determined using a clinical
isolate of C. albicans (Table 8). Whereas the free ligands,
with the exception CcaH, were ineffective in preventing
the growth of the organism, the Ag(I) complexes of the
hydroxylated coumarin acids displayed moderate activity.
Only [Ag(6-OHCca)] (28) (MIC80 = 34.1 lM) was more
active than AgNO3 (MIC80 = 66.8 lM) and was compara-
ble in activity to the commercially available fungicide keto-
conazole (MIC80 = 25 lM) [27].4. Conclusions
A number of new Ag(I) coumarin–carboxylate com-
plexes exhibit potent antibacterial and anti-Candida activ-
ity. Of particular note is the high potency of the
complexes against the clinically important MRSA bacte-
rium. Whilst in general hydroxylation of the aromatic ring
of the coumarin ligand appears to be important for confer-
ring antimicrobial activity, the most active Ag(I) complex
MRSA was that of the unsubstituted coumarin carboxylate
ligand, CcaH. Currently, studies are underway to deter-
mine the mechanism of action of these complexes.Acknowledgement
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